Dr. González has consistently elevated Diopsys’ clinical research and product development efforts since he started working with us seven years ago.
(PRWEB) August 01, 2017
Diopsys, Inc., the leading provider of modern visual electrophysiology medical devices, announced today the appointment of neuro-ophthalmologist Alberto González García, M.D. as Chief Medical Officer. The promotion of Dr. González is in line with the company’s commitment to providing eye care specialists with the objective, functional information they need for early diagnosis of vision disorders, and enhanced patient management through electroretinography (ERG) and visual evoked potential (VEP) vision testing.
Dr. González joined Diopsys, Inc. in September 2010 as Research Director and Chairman of the Diopsys Scientific and Medical Advisory Board. In this role, he helped lead Diopsys clinical, scientific, and engineering efforts to develop the most advanced, patient-friendly visual electrophysiology devices available. Dr. González has published and contributed to numerous books and studies in the areas of early diagnosis of glaucoma, ischemic optic neuropathy, and optic coherence tomography (OCT) in the diagnosis of retinal and optic nerve diseases, among many others. He is also a patent holder on the non-invasive Diopsys® ERG Lid Sensor, and the inventor of Diopsys® CORDA, software that uses existing OCT images to better discriminate different components of the RNFL.
“Dr. González has consistently elevated Diopsys’ clinical research and product development efforts since he started working with us seven years ago. It is with great pleasure and gratitude that we recognize his contributions and look forward to his continued success as our new Chief Medical Officer,” said Joseph Fontanetta, Diopsys President and CEO. “With an extensive list of research studies currently in progress and a backlog of studies yet to begin, we are confident our clinical programs are in good hands.”
Prior to joining Diopsys, Dr. González received his medical training at Finlay-Albarran in Havana, Cuba. He completed his fellowship in neuro-ophthalmology at the National Institute of Neurology and Neurosurgery in Cuba, and in glaucoma at the Hamilton Glaucoma Center at the University of California, San Diego. He was also chief of the Neuro-Ophthalmology Department at the National Institute of Neurology and Neurosurgery, and a clinician and surgeon at the National Institute of Ophthalmology in Cuba.
About Diopsys Inc.
Diopsys, Inc. (http://diopsys.com/) is the world leader in modern visual electrophysiology for the eye care practice. The company’s unique, patented technology provides ophthalmologists and optometrists with objective, functional information about the health of the vision system to aid in the early detection of vision disorders, and post-treatment tracking for enhanced patient management.